Revenue and Financial Performance - ADMA Biologics, Inc. announced preliminary unaudited full year 2024 revenue[6] - Future guidance and performance outlook will be provided in subsequent reports[6] Market Strategy - The company is focused on expanding its market presence and enhancing product offerings[6]

Financial Performance - Total revenue for FY 2024 reached $426.5 million, marking a 65% year-over-year increase from $258.2 million in FY 2023 [14][16] - GAAP net income for FY 2024 was $197.7 million, a significant turnaround from a net loss of $28.2 million in FY 2023 [16] - Adjusted EBITDA for FY 2024 was $164.6 million, reflecting a 309% increase compared to $40.2 million in FY 2023 [17] - Adjusted net income for FY 2024 was $119.2 million, a dramatic rise from $0.7 million in FY 2023, representing a 16,810% increase [17] Cash Flow and Balance Sheet - Year-end 2024 total cash grew to over $103 million, including $60 million of debt that was organically discharged during the second half of 2024 [18] - The company generated approximately $48 million in operating cash flow in Q4 2024, contributing to a strong cash position [7] Future Guidance - Total revenue guidance for FY 2025 and 2026 has been increased to more than $490 million and $605 million, respectively [4] - Adjusted net income guidance for FY 2025 and 2026 has been raised to more than $175 million and $235 million, respectively [4] - Adjusted EBITDA guidance for FY 2025 and 2026 has been increased to more than $225 million and $305 million, respectively [7] Strategic Developments - The company anticipates generating over $1 billion in total annual revenue prior to 2030, more than doubling the current 2025 revenue forecast [2] - Long-term high-titer plasma supply contracts are expected to provide a foundation for durable ASCENIV revenue growth through the late 2030s [3][7] - FDA approval of a yield enhancement production process is anticipated by mid-2025, which could increase production yields by approximately 20% [3][7] Market Position and Product Demand - ASCENIV demand is projected to drive record highs into 2025, with expectations for increased penetration in the complex and refractive primary immunodeficiency (PI) target market [7] - The company has executed long-term high-titer plasma supply contracts, significantly increasing access to raw material plasma used for ASCENIV production [7]

Group 1 - Adma Biologics has an average brokerage recommendation (ABR) of 1.00, indicating a Strong Buy based on recommendations from three brokerage firms, all of which are Strong Buy [2][4] - The ABR is calculated solely from brokerage recommendations, which may not always align with actual stock performance due to potential biases from the firms [5][9] - The Zacks Rank, a separate quantitative model based on earnings estimate revisions, provides a more reliable indicator of near-term stock price performance compared to the ABR [7][10] Group 2 - The Zacks Consensus Estimate for Adma Biologics remains unchanged at $0.51, suggesting analysts have steady views on the company's earnings prospects [12] - Due to the unchanged consensus estimate and other factors, Adma Biologics holds a Zacks Rank 3 (Hold), indicating a cautious approach despite the Strong Buy ABR [13]

Conference Call Scheduled for March 3, 2025, at 4:30 p.m. ETRAMSEY, N.J. and BOCA RATON, Fla., Feb. 25, 2025 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced that it will report fourth quarter and full year 2024 financial results on March 3, 2025, after the U.S. financial markets close. ADMA’s management team will host a live conferen ...

Company Performance - Adma Biologics (ADMA) closed at $16.07, down 0.62% from the previous trading session, underperforming the S&P 500's gain of 0.24% [1] - Over the past month, shares of Adma Biologics have gained 0.06%, lagging behind the Medical sector's gain of 3.63% and the S&P 500's gain of 2.37% [1] Financial Projections - The upcoming earnings per share (EPS) for Adma Biologics is projected to be $0.15, representing a 275% increase from the same quarter last year [2] - Revenue is estimated to be $112.2 million, reflecting a 51.83% increase from the prior-year quarter [2] Analyst Forecasts - Recent revisions to analyst forecasts for Adma Biologics are important as they indicate evolving short-term business trends, with positive revisions suggesting optimism about the company's outlook [3] - The Zacks Rank system, which incorporates estimate changes, aims to provide actionable ratings based on these revisions [4] Zacks Rank and Valuation - Adma Biologics currently holds a Zacks Rank of 3 (Hold), with the consensus EPS estimate moving 2.24% higher over the past month [5] - The company has a Forward P/E ratio of 23.61, which is a premium compared to the industry average Forward P/E of 22.58 [6] Industry Context - The Medical - Biomedical and Genetics industry, which includes Adma Biologics, holds a Zacks Industry Rank of 68, placing it in the top 28% of over 250 industries [6] - The Zacks Industry Rank measures the strength of industry groups based on the average Zacks Rank of individual stocks, indicating that top-rated industries outperform lower-rated ones by a factor of 2 to 1 [7]

Pharmaceutical concern ADMA Biologics Inc (NASDAQ:ADMA) has been consolidating above familiar pressure at the $16 region since mid-January. A breakout could be on the way, however, as the stock just came into contact with a historically bullish trendline. Per Schaeffer's Senior Quantitative Analyst Rocky White, ADMA has come within striking distance of its 200-day moving average after a lengthy period above it (defined by White as 80% of the time over the past two months and 8 of the last 10 trading days). ...

ADMA Biologics’ (ADMA) shares have lost 8.9% in a month against the industry’s growth of 6.6%.The company has put up a phenomenal performance in 2024 and hit a 52-week high of $23.64 on Nov. 11.Last month, ADMA reported preliminary revenues for 2024 and provided a business update. On a preliminary basis, total revenues in 2024 are estimated to be in the $417-$425 million range (exceeding previous guidance of $415 Million). Total cash holdings at the end of 2024 grew to more than $100 million.ADMA Underperfo ...

Adma Biologics (ADMA) ended the recent trading session at $16.92, demonstrating a +0.3% swing from the preceding day's closing price. The stock lagged the S&P 500's daily gain of 0.36%. Meanwhile, the Dow experienced a drop of 0.28%, and the technology-dominated Nasdaq saw an increase of 0.51%.Coming into today, shares of the infectious disease drug developer had lost 9.11% in the past month. In that same time, the Medical sector gained 5.92%, while the S&P 500 gained 2.11%.Investors will be eagerly watchin ...

This is my first cover of ADMA Biologics (NASDAQ: ADMA ). In the article, I will describe ADMA Biologics' business areas and my opinion on how they will affect the company's future. I will try to compare ADMA's product to the competition andI first entered investing in 2016 as an individual value investor. In 2022, I established the investment firm Libra Capital. I mostly write articles as part of my deep research into a company before I make an investment, whether long or short. For me, a ''hold'' article ...

Core Viewpoint - Adma Biologics is experiencing fluctuations in stock performance, with a recent increase in share price, but a decline over the past month, while upcoming financial results are anticipated to show significant year-over-year growth in earnings and revenue [1][2]. Group 1: Stock Performance - Adma Biologics shares closed at $16.47, reflecting a +1.92% change from the previous day, outperforming the S&P 500's gain of 0.61% [1] - Over the past month, shares have decreased by 7.18%, underperforming both the Medical sector's gain of 1.64% and the S&P 500's gain of 2.08% [1] Group 2: Financial Expectations - Analysts expect Adma Biologics to report earnings of $0.15 per share, indicating a year-over-year growth of 275% [2] - Revenue is forecasted to be $112.2 million, representing a 51.83% increase compared to the same quarter last year [2] Group 3: Analyst Projections - Recent shifts in analyst projections for Adma Biologics are important for investors, as positive changes indicate optimism regarding the company's business and profitability [3] - The Zacks Rank system, which incorporates these estimate changes, suggests a correlation between estimate adjustments and stock price performance [4] Group 4: Zacks Rank and Valuation - Adma Biologics currently holds a Zacks Rank of 3 (Hold), with a consensus EPS projection that has decreased by 11.61% in the past 30 days [5] - The company has a Forward P/E ratio of 23.59, which is higher than the industry average of 21.95, indicating it is trading at a premium [6] Group 5: Industry Context - The Medical - Biomedical and Genetics industry, to which Adma Biologics belongs, has a Zacks Industry Rank of 72, placing it in the top 29% of over 250 industries [6] - The Zacks Industry Rank assesses the strength of industry groups, with top-rated industries outperforming lower-rated ones by a factor of 2 to 1 [7]